Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc (NQ: XENE )

39.33 -1.09 (-2.70%)
Streaming Delayed Price Updated: 2:45 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xenon Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million. 
Via Benzinga
Earnings Preview: Xenon Pharmaceuticals
Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Xenon... 
Via Benzinga
Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Analyst Sees This Epilepsy Player As 'M&A Sweet Spot'
Via Benzinga
4 Analysts Have This to Say About Xenon Pharmaceuticals
Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings: 
Via Benzinga
Xenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset Seizures
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Hurry! 7 Pitiful Nasdaq Stocks to Sell Before 2022 Ends.
As the Fed continues to tighten the market, consider putting these seven on your list of overvalued Nasdaq stocks to sell before 2022 ends. 
Via InvestorPlace
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Analyst Ratings for Xenon Pharmaceuticals
Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings within the last quarter: 
Via Benzinga
4 Analysts Have This to Say About Xenon Pharmaceuticals
  Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings: 
Via Benzinga
Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency
Via Benzinga
Xenon Pharmaceuticals Shares Drop On Proposed Public Offering
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022
Upgrades 
Via Benzinga
Recap: Xenon Pharmaceuticals Q1 Earnings
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Swing Trading Stock Watchlist For The Week Of Sept. 6
The overall stock market health is poor. I created a watchlist this week mainly to see how many stocks were forming quality contraction or cup-and-handle patterns. Let's take a look. 
Via Talk Markets
Xenon Pharmaceuticals May Have A Blockbuster Drug In Store, BofA Says
Xenon Pharmaceuticals Inc’s (NASDAQ: XENE) epilepsy candidate, XEN1101, is currently in phase III trials and “looks poised to be a blockbuster,” according to BofA Securities. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022
Upgrades 
Via Benzinga
What 4 Analyst Ratings Have To Say About Xenon Pharmaceuticals
  Analysts have provided the following ratings for Xenon Pharmaceuticals (NASDAQ:XENE) within the last quarter: 
Via Benzinga
Xenon Pharmaceuticals: Q2 Earnings Insights
  Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter. 
Via Benzinga
Earnings Outlook For Xenon Pharmaceuticals
  Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Xenon Pharma Flirted With A Breakout — And Then Sacrificed It All
The company had bullish results in seizure treatment. But it wasn't enough. 
Via Investor's Business Daily
US Stock Futures Mixed Ahead Of Jobless Claims, Powell Testimony
Pre-open movers 
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid... 
Via Benzinga
Looking Into Xenon Pharmaceuticals's Return On Capital Employed
According to Benzinga Pro data, during Q1, Xenon Pharmaceuticals (NASDAQ:XENE) posted sales of $8.77 million. Earnings were up 23.06%, but Xenon Pharmaceuticals still reported an overall loss of $19.67... 
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.